BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 29945611)

  • 21. DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease.
    Schmidt ME; Caron NS; Aly AE; Lemarié FL; Dal Cengio L; Ko Y; Lazic N; Anderson L; Nguyen B; Raymond LA; Hayden MR
    Front Cell Neurosci; 2020; 14():590569. PubMed ID: 33250715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.
    Creus-Muncunill J; Ehrlich ME
    Neurotherapeutics; 2019 Oct; 16(4):957-978. PubMed ID: 31529216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease-toxicant interactions in manganese exposed Huntington disease mice: early changes in striatal neuron morphology and dopamine metabolism.
    Madison JL; Wegrzynowicz M; Aschner M; Bowman AB
    PLoS One; 2012; 7(2):e31024. PubMed ID: 22363539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease.
    Cummings DM; Cepeda C; Levine MS
    ASN Neuro; 2010 Jun; 2(3):e00036. PubMed ID: 20585470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
    Li L; Murphy TH; Hayden MR; Raymond LA
    J Neurophysiol; 2004 Nov; 92(5):2738-46. PubMed ID: 15240759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological gamma oscillations, impaired dopamine release, synapse loss and reduced dynamic range of unitary glutamatergic synaptic transmission in the striatum of hypokinetic Q175 Huntington mice.
    Rothe T; Deliano M; Wójtowicz AM; Dvorzhak A; Harnack D; Paul S; Vagner T; Melnick I; Stark H; Grantyn R
    Neuroscience; 2015 Dec; 311():519-38. PubMed ID: 26546830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural and functional features of medium spiny neurons in the BACHDΔN17 mouse model of Huntington's Disease.
    Goodliffe J; Rubakovic A; Chang W; Pathak D; Luebke J
    PLoS One; 2020; 15(6):e0234394. PubMed ID: 32574176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
    McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
    Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
    Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
    J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.
    Thomas EA; Coppola G; Tang B; Kuhn A; Kim S; Geschwind DH; Brown TB; Luthi-Carter R; Ehrlich ME
    Hum Mol Genet; 2011 Mar; 20(6):1049-60. PubMed ID: 21177255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
    Xie Y; Hayden MR; Xu B
    J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.
    Milnerwood AJ; Raymond LA
    J Physiol; 2007 Dec; 585(Pt 3):817-31. PubMed ID: 17947312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Rogers DA; Bissada N; Vogl AW; Hayden MR; Leavitt BR
    Hum Mol Genet; 2005 May; 14(10):1379-92. PubMed ID: 15829505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.
    Naydenov AV; Sepers MD; Swinney K; Raymond LA; Palmiter RD; Stella N
    Neurobiol Dis; 2014 Nov; 71():140-50. PubMed ID: 25134728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
    Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
    Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
    Brown TB; Bogush AI; Ehrlich ME
    Hum Mol Genet; 2008 Oct; 17(20):3095-104. PubMed ID: 18632688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of cortical synaptic input on striatal neuronal dendritic arborization and sensitivity to excitotoxicity in corticostriatal coculture.
    Buren C; Tu G; Parsons MP; Sepers MD; Raymond LA
    J Neurophysiol; 2016 Aug; 116(2):380-90. PubMed ID: 27121581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors.
    Ruiz-Calvo A; Maroto IB; Bajo-Grañeras R; Chiarlone A; Gaudioso Á; Ferrero JJ; Resel E; Sánchez-Prieto J; Rodríguez-Navarro JA; Marsicano G; Galve-Roperh I; Bellocchio L; Guzmán M
    Cereb Cortex; 2018 Jan; 28(1):307-322. PubMed ID: 29121220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.